Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

renal cell carcinoma

- PMLiVE

Priority review for Keytruda in head and neck cancer

FDA assessment raises prospect of third indication for Merck & Co's immuno-oncology drug

Gilead Sciences

Gilead must pay just $200m for hep C patents, says jury

Merck & Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

- PMLiVE

Sanofi and Merck & Co dissolve longstanding vaccines alliance

Lacklustre sales at Sanofi Pasteur MSD prompts split

- PMLiVE

Merck and Sun Pharma part company on branded generics

Will continue partnership on diabetes and inflammatory disorder projects

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

- PMLiVE

Germany’s Merck triumphs in court battle with US namesake

English court rules Merck & Co breached the firms' naming agreement

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

- PMLiVE

Syndax teams with Merck/Pfizer on immuno-oncology combo

Oral cancer drug entinostat to test with avelumab

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

MSD appoints Jessica Fine as UK external affairs director

She joins the UK pharma company from Lexington Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links